Alto Neuroscience (NYSE:ANRO) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Alto Neuroscience (NYSE:ANRO) from a hold rating to a sell rating in a report released on Saturday morning,Wall Street Zen reports.

A number of other research analysts also recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alto Neuroscience in a report on Wednesday, July 29th. Zacks Research raised Alto Neuroscience from a “strong sell” rating to a “hold” rating in a report on Thursday, August 20th. HC Wainwright upped their price target on Alto Neuroscience from $50.00 to $55.00 and gave the company a “buy” rating in a report on Monday, August 17th. Wolfe Research started coverage on shares of Alto Neuroscience in a research note on Friday, May 22nd. They issued an “outperform” rating on the stock. Finally, BTIG Research raised their price objective on shares of Alto Neuroscience from $28.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $37.25.

Alto Neuroscience Stock Performance

Shares of ANRO stock opened at $31.83 on Friday. The company has a market cap of $1.25 billion, a P/E ratio of -13.15 and a beta of 1.13. The firm has a fifty day moving average price of $30.79 and a 200 day moving average price of $25.47. The company has a current ratio of 14.85, a quick ratio of 14.85 and a debt-to-equity ratio of 0.07. Alto Neuroscience has a 12 month low of $3.59 and a 12 month high of $37.48.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.08. Sell-side analysts predict that Alto Neuroscience will post -2.68 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Alto Neuroscience by 14,567.0% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 212,672 shares of the company’s stock valued at $3,786,000 after buying an additional 211,222 shares during the last quarter. AWM Investment Company Inc. acquired a new stake in shares of Alto Neuroscience during the second quarter worth about $2,111,000. Jennison Associates LLC purchased a new position in shares of Alto Neuroscience during the first quarter worth about $8,687,000. Perceptive Advisors LLC raised its stake in Alto Neuroscience by 12.6% during the 1st quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock valued at $45,182,000 after acquiring an additional 225,500 shares during the last quarter. Finally, Orbimed Advisors LLC lifted its position in Alto Neuroscience by 34.0% during the 1st quarter. Orbimed Advisors LLC now owns 167,500 shares of the company’s stock worth $3,765,000 after acquiring an additional 42,500 shares during the period.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with neuropsychiatric disorders. The company combines clinical data, biological measurements and digital assessments to identify patient characteristics that may help predict treatment response and guide the development of more targeted therapies.

Alto’s pipeline has included investigational treatments for conditions such as major depressive disorder and schizophrenia.